BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32235752)

  • 1. Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives.
    Weenink B; French PJ; Sillevis Smitt PAE; Debets R; Geurts M
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32235752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of glioblastoma immunotherapy.
    Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
    J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives.
    Yang M; Oh IY; Mahanty A; Jin WL; Yoo JS
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32824974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy Resistance in Glioblastoma.
    Wang EJ; Chen JS; Jain S; Morshed RA; Haddad AF; Gill S; Beniwal AS; Aghi MK
    Front Genet; 2021; 12():750675. PubMed ID: 34976006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy for brain tumors: obstacles and perspectives].
    Migliorini D; Dietrich PY
    Rev Med Suisse; 2016 Apr; 12(516):828-31. PubMed ID: 27281940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
    Zhang N; Wei L; Ye M; Kang C; You H
    Front Immunol; 2020; 11():592612. PubMed ID: 33329578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Checkpoint Inhibitors in Glioblastoma.
    Desai K; Hubben A; Ahluwalia M
    Target Oncol; 2019 Aug; 14(4):375-394. PubMed ID: 31290002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
    Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
    J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
    Farrell C; Shi W; Bodman A; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier.
    Frederico SC; Darling C; Bielanin JP; Dubinsky AC; Zhang X; Hadjipanayis CG; Kohanbash G
    Front Immunol; 2023; 14():1057567. PubMed ID: 36875096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in Glioblastoma: A Clinical Perspective.
    Desbaillets N; Hottinger AF
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
    Sener U; Ruff MW; Campian JL
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.